SEC Form 4 · accession 0001209191-15-054843
EAGLE PHARMACEUTICALS, INC. · EGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven L. Krill
Officer — Chief Scientific Officer
Period of report
Jun 16, 2015
Accepted (ET)
Jun 18, 2015 · 8:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827871
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 16, 2015 | M | 5,850 | $8.78 | A | 5,850 | D | |
| Common StockF1 | Jun 16, 2015 | S | 5,850 | $81.60 | D | 0 | D | |
| Common Stock | Jun 16, 2015 | M | 2,730 | $8.78 | A | 2,730 | D | |
| Common StockF2 | Jun 16, 2015 | S | 2,730 | $81.60 | D | 0 | D | |
| Common Stock | Jun 16, 2015 | M | 1,400 | $4.42 | A | 1,400 | D | |
| Common StockF2 | Jun 16, 2015 | S | 1,400 | $81.60 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $8.78 | Jun 16, 2015 | M | 5,850 | D | — | Sep 25, 2021 | Common Stock | 5,850 | 1,950 | D |
| Stock Option (right to buy)F4 | $8.78 | Jun 16, 2015 | M | 2,730 | D | — | Jul 11, 2022 | Common Stock | 2,730 | 2,730 | D |
| Stock Option (right to buy)F5 | $4.42 | Jun 16, 2015 | M | 1,400 | D | — | Apr 18, 2023 | Common Stock | 1,400 | 20,517 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.73 to $82.76, inclusive. The reporting person undertakes to provide to Eagle Pharmaceuticals, Inc., any security holder of Eagle Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnotes (1) and (2) to this Form 4.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $80.73 to $82.76, inclusive.
- F325% of the shares subject to the option vested on September 26, 2012 and the remainder shall vest in equal monthly installments over a period of three years.
- F425% of the shares subject to the option vested on July 12, 2013 and the remainder shall vest in equal monthly installments over a period of three years.
- F525% of the shares subject to the option vested on April 19, 2014 and the remainder shall vest in equal monthly installments over a period of three years.